Search results
Results from the WOW.Com Content Network
Common side effects include sedation, fatigue, weight gain, constipation, and dry mouth. [11] Other side effects include low blood pressure with standing, seizures, a prolonged erection, high blood sugar, tardive dyskinesia, and neuroleptic malignant syndrome. [11] In older people with dementia, its use increases the risk of death. [11]
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. ... “make sure your new diet is rich in muscle-building ...
They worked primarily by suppressing appetite, and had other beneficial effects such as increased alertness. Use of amphetamines increased over the subsequent decades, including Obetrol and culminating in the "rainbow diet pill" regime. [38] This was a combination of multiple pills, all thought to help with weight loss, taken throughout the day.
In the amycretin trial, the side effects were related to gastrointestinal discomfort, including nausea and vomiting, similar to those seen in trials of its other medicines from the same GLP-1 drug ...
Megestrol acetate is used mainly as an appetite stimulant to promote weight gain in a variety of situations. [25] [26] [27] When given at very high dosages, it can substantially increase appetite in most individuals, even those with advanced cancer, and is often used to boost appetite and induce weight gain in patients with cancer or HIV/AIDS-associated cachexia. [25]
While Viagra typically works for just a few hours, Rhino claims the effects of a single pill can last seven, nine, or even 14 days. Yikes. Rhino pills could illegally contain sildenafil.
Rimonabant is a selective CB 1 receptor blocker and was discovered and developed by Sanofi-Aventis. [6]On 21 June 2006, the European Commission approved the sale of rimonabant in the then-25-member European Union as a prescription drug for use in conjunction with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m 2, or patients with a BMI greater than 27 kg/m 2 ...